Edwards Lifesciences revenue and financials

EW · NYSE · USD

$86.48−0.86%−$0.75

Close · October 6, 2026

In the fiscal year ended December 2025, Edwards Lifesciences reported revenue of $6.07B (+11.55% year over year). Net income was $1.07B, a net margin of 17.7%.

Annual revenue · 2025: $6.07B
  1. $2.96B2016
  2. $3.44B2017
  3. $3.72B2018
  4. $4.35B2019
  5. $4.39B2020
  6. $5.23B2021
  7. $4.46B2022
  8. $5.01B2023
  9. $5.44B2024
  10. $6.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+11.55%
2025 vs 2024
Net income growth
−74.28%
2025 vs 2024
Net margin
17.7%
2024: 76.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1,7411,6491,5701,5531,5321,4131,3861,3541,3691,3301,2661,243
Cost of revenue392363343345344302292263276287251251
Gross profit1,3491,2861,2271,2081,1881,1111,0941,0921,0941,0431,015993
Selling, general and administrative561522601515502466491421448428415382
Research and development279263268281276255271253272257242243
Operating income520515372425431410354394375358534368
EBIT520515372425431410354394375358534368
EBITDA562556415464469447397417414396571405
Interest expense——20.4———19.8———17.6—
Pre-tax income52045990.4348400434390403384371367388
Income tax27878.326.256.164.370.345.140.720.046.334.152.7
Net income24238191.22913333583863,071366352370385
Net income to common shareholders24238191.22913333583863,071366352370385
Basic EPS0.420.660.160.500.570.610.655.140.610.580.610.63
Diluted EPS0.420.660.150.500.560.610.655.140.610.580.610.63
Average shares (basic)576579580585587587590597602602605607
Average shares (diluted)578581582586588588591598604604607610